drugset / Trial / NCT04521023

A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

NCT04521023

Phase 4 Completed 132 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients

Timeline

Start
2017-09-20
Primary completion
2020-01-28
Completion
2020-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified
Comparator Hydrochlorothiazide Unknown
Comparator Candesartan Unknown

Indications